Sage Journals: Discover world-class research

Abstract

Introduction:

The expression of alpha-five beta-three (αVβ3) integrins is upregulated in various malignancies undergoing angiogenesis. The development of integrin antagonists as diagnostic probes makes the αVβ3 integrin a suitable candidate for targeting tumor angiogenesis. The goal of this study was to optimize the radiolabeling and evaluate the potential of conjugated integrin antagonist carbamate (IAC), a peptidomimetic, as a theranostic radiopharmaceutical for targeting tumor angiogenesis.

Methodology:

Radiolabeling of DOTAGA [2,2′,2”–{10-(2,6-dioxotetrahydro-2H-pyran-3-yl)−1,4,7,10-tetraazacyclododecane-1,4,7-triyl} triacetic-acid]-IAC with [⁶⁸Ga]Ga, [¹⁷⁷Lu]Lu, and [²²⁵Ac]Ac was optimized. The binding affinity (K_d) of DOTAGA-IAC for the αVβ3 receptor and cancer cell lines was quantified. The biodistribution studies were conducted in healthy Wistar rats. Dosimetry analysis was performed on [¹⁷⁷Lu]Lu-DOTAGA-IAC distribution data. A pilot study of [⁶⁸Ga]Ga-DOTAGA-IAC and [¹⁸F]FDG Positron Emission Tomography (PET/CT) imaging was performed in five patients with histopathologically confirmed breast cancer. PET/CT findings were compared between [⁶⁸Ga]Ga-DOTAGA-IAC and [¹⁸F]FDG in these patients.

Results:

Radiopharmaceuticals were prepared with high radiochemical purity (>99.9%). K_d and B_max measurements were 15.02 nM and 417 fmol for αVβ3 receptor protein: 115.7 nM and 295.3 fmol for C6 glioma cells. Biodistribution studies in rats suggested the excretion via kidneys and partially through the hepatobiliary route. The effective dose of [¹⁷⁷Lu]Lu-DOTAGA-IAC was found to be 0.17 mSv/MBq. The dynamic study in patients revealed the optimal imaging time to be 30–35 mins postadministration. Out of the cohort, [⁶⁸Ga]Ga-DOTAGA-IAC detected the primary lesions in all five patients with a mean standard uptake value (SUV_max) of 3.94 ± 0.58 compared with [¹⁸F]FDG (SUV_max 13.8 ± 6.53).

Conclusion:

The study demonstrates that DOTAGA-IAC exhibits strong binding to αVβ3 integrin, positioning it as a promising PET agent for assessing primary and metastatic cancers. The outcomes from the pilot study suggest the potential of [⁶⁸Ga]Ga-DOTAGA-IAC PET/CT in breast carcinoma diagnosis. While recognizing the theranostic potential of DOTAGA-IAC for αVβ3 integrin-expressing tumors, further clinical investigations are warranted to comprehensively assess therapeutic efficacy.

Get full access to this article

View all access options for this article.

References

Folkman

. Tumor angiogenesis: Therapeutic implications. N Engl J Med, 1971; 285(21):1182–1186.

Carmeliet

. Mechanisms of angiogenesis and arteriogenesis. Nat Med, 2000; 6(4):389–395.

Nussenbaum

, Herman

. Tumor angiogenesis: Insights and innovations. J Oncol, 2010; 2010:132641.

Francavilla

, Maddaluno

, Cavallaro

. The functional role of cell adhesion molecules in tumor angiogenesis. Semin Cancer Biol, 2009; 19(5):298–309.

Desgrosellier

, Cheresh

. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer, 2010; 10(1):9–22.

Danhier

, Le Breton

, Préat

. RGD-based strategies to target alpha (v) beta (3) integrin in cancer therapy and diagnosis. Mol Pharmaceutics, 2012; 9(11):2961–2973.

Brooks

, Strömblad

, Klemke

, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest, 1995; 96(4):1815–1822.

Takayama

, Ishii

, Ikeda

, et al. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res, 2005; 25(1A):79−–83.

Uhm

, Dooley

, Kyritsis

, et al. Vitronectin, a Glioma-derived extracellular Matrix Protein, protects tumor cells from apoptotic death. Clin Cancer Res, 1999; 5(6):1587–1594.

10.

Hosotani

, Kawaguchi

, Masui

, et al. Expression of integrin alphaVbeta3 in pancreatic carcinoma: Relation to MMP-2 activation and lymph node metastasis. Pancreas, 2002; 25(2):e30–e35.

11.

Cooper

, Chay

, Pienta

. The Role of alpha (v) beta (3) in Prostate Cancer Progression. Neoplasia, 2002; 4(3):191–194.

12.

Chattopadhyay

, Chatterjee

. Studies on the Expression of alpha v beta 3 Integrin Receptors in Non-malignant and Malignant Human Cervical Tumor Tissues. J Exp Clin Cancer Res, 2001; 20(2):269–275.

13.

Beer

, Schwaiger

. Imaging of integrin αvβ3 expression. Cancer Metastasis Rev, 2008; 27(4):631–644.

14.

Debordeaux

, Chansel-Debordeaux

, Pinaquy

, et al. What about αvβ3 integrins in molecular imaging in oncology? Nucl Med Biol, 2018; 62-63:31–46.

15.

Knetsch

, Petrik

, Griessinger

, et al. [68 Ga] NODAGA-RGD for imaging αvβ3 integrin expression. Eur J Nucl Med Mol Imaging, 2011; 38(7):1303–1312.

16.

Dijkgraaf

, Yim

, Franssen

, et al. PET imaging of α_vβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di-and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging, 2011; 38(1):128–137.

17.

Pohle

, Notni

, Bussemer

, et al. ⁶⁸Ga-NODAGA-RGD is a suitable substitute for ¹⁸F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol, 2012; 39(6):777–784.

18.

Vatsa

, Shukla

, Kumar

, et al. Effect of Macro-Cyclic Bifunctional Chelators DOTA and NODAGA on Radiolabeling and In Vivo Biodistribution of Ga-68 Cyclic RGD Dimer. Cancer Biother Radiopharm, 2019; 34(7):427–435.

19.

Hsu

, Veeravagu

, Cai

, et al. Integrin αvβ3 antagonists for anti-angiogenic cancer treatment. Recent Pat Anticancer Drug Discov, 2007; 2(2):143–158.

20.

Jang

, Lim

, Park

, et al. Radiolabeled high affinity peptidomimetic antagonist selectively targets αvβ3 receptor-positive tumor in mice. Nucl Med Biol, 2007; 34(4):363–370.

21.

Shin

, Maeng

, Jang

, et al. 99mTc-labeling of peptidomimetic antagonist to selectively target αvβ3 receptor-positive tumor: Comparison of PDA (Parenteral Drug Association)and EDDA as co-ligands. Curr Radiopharm, 2010; 3(1):1–8.

22.

Kim

, Nwe

, Milenic

, et al. Synthesis and characterization of αvβ3-targeting peptidomimetic chelate conjugates for PET and SPECT imaging. Bioorg Med Chem Lett, 2012; 22(17):5517–5522.

23.

Baum

, Kulkarni

, Müller

, et al. First-in-human study demonstrating tumor-angiogenesis by PET/CT imaging with 68Ga-NODAGA-THERANOST, a high-affinity peptidomimetic for αvβ3 integrin receptor targeting. Cancer Biother Radiopharm, 2015; 30(4):152–159.

24.

Price

, Orvig

. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev, 2014; 43(1):260–290.

25.

Kirschner

, Ice

, Beierwaltes

. Radiation dosimetry of 131I-19-iodocholesterol: The pitfalls of using tissue concentration data, the author’s reply. J Nucl Med, 1975; 16(3):248–249.

26.

Foster

, Barrett

. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. In: Proc. Sixth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge Institute for Science and Education, in press, 1998.

27.

Stabin

, Siegel

. Physical models and dose factors for use in internal dose assessment. Health Phys, 2003; 85(3):294–310.

28.

Stabin

, Sparks

, Crowe

. OLINDA/EXM: The Second-Generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med, 2005; 46(6):1023–1027.

29.

Kelly

, Amor-Coarasa

, Sweeney

, et al. A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals. EJNMMI Radiopharm Chem, 2021; 6(1):38–34.

30.

Xie

, Liu

, Ding

, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F] AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga] Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging, 2021; 48(10):3129–3140.

31.

Wang

, Shao

, Wu

, et al. Preparation of 68Ga-PSMA-11 with a synthesis module for micro-PET-CT imaging of PSMA expression during prostate cancer progression. Contrast Media Mol Imaging, 2018; 2018:1–9.

32.

Antunes

, Ginj

, Zhang

, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging, 2007; 34(7):982–993.

33.

Cheal

, Chung

, Vaughn

, et al. Pretargeting: A path forward for radioimmunotherapy. J Nucl Med, 2022; 63(9):1302–1315.

34.

Okamoto

, Thieme

, Allmann

, et al. Radiation dosimetry for 177Lu-PSMA IT in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions. J Nucl Med, 2017; 58(3):445–450.

35.

Kind

, Michalski

, Yousefzadeh-Nowshahr

, et al. Bone marrow impairment during early [177Lu] PSMA-617 radioligand therapy: Haematotoxicity or tumour progression? EJNMMI Res, 2022; 12(1):20.

36.

Wahl

, Sgouros

, Iravani

, et al. Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns. J Nucl Med, 2021; 62(Suppl 3):23S–35S.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.33 MB

Advancing Cancer Theranostics Through Integrin αVβ3-Targeted Peptidomimetic IAC: From Bench to Bedside